TARRYTOWN, N.Y., Feb. 8 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) today announced that it will present at
the BIO CEO & Investor Conference, taking place on February 12-14, 2007 at
the Waldorf- Astoria Hotel in New York City. Lewis H. Bender, President and
Chief Executive Officer, will present on Wednesday, February 14 at 12:00
p.m. ET.
A live audio webcast of Emisphere's presentation will be available on
the Investor Relations section of the Company's web site at
http://www.emisphere.com/ir.asp or directly at: http://www.corporate-
ir.net/ireye/conflobby.zhtml?ticker=EMIS&item_id=1450947
Please visit the website at least five minutes prior to start time for
instructions. A replay of the presentation will be available on the
Investor Relations portion of Emisphere's website approximately one hour
after the presentation through March 14, 2007.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company pioneering
the oral delivery of otherwise injectable drugs. Emisphere's business
strategy is to develop oral forms of injectable drugs, either alone or with
corporate partners, by applying its proprietary eligen(R) technology to
those drugs or licensing its eligen(R) technology to partners who typically
apply it directly to their marketed drugs. Emisphere's eligen(R) technology
has enabled the oral delivery of proteins, peptides, macromolecules and
charged organics. Emisphere and its partners have advanced oral
formulations or prototypes of salmon calcitonin, heparin, insulin,
parathyroid hormone, human growth hormone and cromolyn sodium into clinical
trials. Emisphere has strategic alliances with world-leading pharmaceutical
companies. For further information, please visit the Emisphere website,
http://www.emisphere.com .
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding the timing or potential
outcomes of research collaborations or clinical trials, any market that
might develop for any of Emisphere's product candidates and the sufficiency
of Emisphere's cash and other capital resources) are forward-looking
statements that involve risks and uncertainties, including, but not limited
to, the likelihood that future research will prove successful, the
likelihood that any product in the research pipeline will receive
regulatory approval in the United States or abroad, the ability of
Emisphere and/or its partners to develop, manufacture and commercialize
products using Emisphere's drug delivery technology, Emisphere's ability to
fund such efforts with or without partners, and other risks and
uncertainties detailed in Emisphere's filings with the Securities and
Exchange Commission, including those factors discussed under the caption
"Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615)
filed on March 16, 2006, and our Quarterly Reports on Form 10-Q for the
quarters ended March 31, 2006, June 30, 2006, and September 30, 2006.
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com
CONTACT:
Stewart Siskind, Investor Relations,
Emisphere Technologies, Inc., +1-914-785-4742; or Dan Budwick,
BMC Communications, +1-212-477-9007 ext. 14
|
